Form 4: Bluebird Bio Executive Joseph Vittiglio Reports Acquisition of 50,000 Shares of Common Stock
SEC Form 4
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., reports the acquisition of 50,000 shares of common stock through restricted stock units.
Summary
- On September 30, 2024, Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., acquired 50,000 shares of common stock.
- These shares were obtained through restricted stock units (RSUs) at a price of $0.00.
- The RSUs vest over a four-year period, with 25% vesting on each of March 1, 2025, March 1, 2026, March 1, 2027, and March 1, 2028.
- Following the transaction, Vittiglio beneficially owns 94,783 shares of bluebird bio, Inc.
- A Power of Attorney was executed on September 23, 2024, appointing Andrew Obenshain and Sydney Gaylin as attorneys-in-fact for Section 13 and 16 filings.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the executive and the company's future. There are no explicit negative indicators.
Positives
- The grant of restricted stock units to a key executive aligns their interests with the long-term performance of the company.
- The vesting schedule encourages continued service and commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the RSUs suggests an expectation of continued employment and contribution from the executive.
Industry Context
Stock grants to key executives are a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders. This is a standard compensation practice.
Comparison to Industry Standards
- Equity compensation is a standard practice among publicly traded biotech companies.
- Companies like Amgen, Gilead, and Vertex regularly grant stock options and restricted stock units to their executives as part of their compensation packages.
- The vesting schedule of four years is also typical, aligning with industry norms for retaining key talent.
Stakeholder Impact
- Shareholders: The grant of RSUs aligns executive interests with shareholder value.
- Employees: The grant may have a positive impact on employee morale as it shows the company is investing in its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-09-23 | Date of Power of Attorney execution. |
| 2024-09-30 | Date of transaction: Acquisition of 50,000 shares of common stock. |
| 2025-03-01 | First vesting date for 25% of the restricted stock units. |
| 2026-03-01 | Second vesting date for 25% of the restricted stock units. |
| 2027-03-01 | Third vesting date for 25% of the restricted stock units. |
| 2028-03-01 | Final vesting date for 25% of the restricted stock units. |
| 2024-10-02 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.